Biotechnology Companies
Board-ready evidence, with no laboratory of your own
One contract covers the computation and the bench work. Most first engagements start at USD 45–75K and deliver inside a quarter.
What we hear
What we hear from founders and CSOs
- No internal laboratory, no computational team, and no intention of building either yet
- A board expecting data-driven progress before the next round closes
- No capacity to manage two suppliers and the hand-off between them
- Decisions that have to be defensible to investors who will diligence them
What we do about it
One workstream, one accountable lead
We work the way a small team needs a partner to work: fast decisions, fixed scope, a named scientist you can call, and an evidence package written so your investors can read it.
Where we typically start
Where we typically start
The Discovery Sprint - USD 45–75K, 6–10 weeks. One computational workstream, an evidence dossier, and a costed plan for what to validate next. Small enough for a CSO to approve without a procurement cycle. Large enough to prove whether the model works for you.
Discovery SprintTarget ValidationVirtual ScreeningLead Optimisation
Speed, honestly
Most emerging-biotech engagements go from first conversation to signed scope in three to ten weeks. We can usually start within three weeks of signature. If we cannot, we will tell you before you ask.
Proof
What it looks like in practice
Forty candidate targets narrowed to a defensible five in seven weeks; the leading two confirmed by knockdown across three primary cell lines; the whole programme delivered in eleven weeks under one contract, and the evidence package used directly in Series B materials.
Representative programme - illustrates typical scope and outcomes; not an individual client account. Client-specific references are available on request under confidentiality.
Enterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.